For hip fracture , at a 15 % relative risk , the effect estimate lay between the futility boundary and the inferior boundary , meaning there is reliable evidence that vitamin D supplementation does not reduce hip fractures by this amount , but uncertainty remains as to whether it might increase hip fractures .
The effect estimate lay within the futility boundary at thresholds of 0·5 % for total hip , forearm , and total body bone mineral density , and 1·0 % for lumbar spine and femoral neck , providing reliable evidence that vitamin D does not alter these outcomes by these amounts .
INTERPRETATION Our findings suggest that vitamin D supplementation does not prevent fractures or falls , or have clinical ly meaningful effects on bone mineral density .
There were no differences between the effects of higher and lower doses of vitamin D. There is little justification to use vitamin D supplements to maintain or improve musculoskeletal health .
BACKGROUND The effects of vitamin D on fractures , falls , and bone mineral density are uncertain , particularly for high vitamin D doses .
We aim ed to determine the effect of vitamin D supplementation on fractures , falls , and bone density .
Can vitamin D3 supplementation prevent bone loss in persons with MS? A placebo-controlled trial
Multiple sclerosis ( MS ) is a possible cause of secondary osteoporosis . In this phase II trial we assessed whether a weekly dose of 20,000 IU vitamin D3 prevents bone loss in ambulatory persons with MS age 18–50 years . Clinical Trials.gov ID NCT00785473 . All patients managed at the University Hospital of North Norway who fulfilled the main inclusion criteria were invited to participate in this double-blinded trial . Participants were r and omised to receive 20,000 IU vitamin D3 or placebo once a week and 500 mg calcium daily for 96 weeks . The primary outcome was the effect of the intervention on percentage change in bone mineral density ( BMD ) at the hip , the spine , and the ultradistal radius over the study period . Of 71 participants r and omised , 68 completed . Mean serum 25-hydroxyvitamin D [ 25(OH)D ] levels in the intervention group increased from 55 nmol/L at baseline to 123 nmol/L at week 96 . After 96 weeks , percentage change in BMD did not differ between groups at any site . BMD decreased at the hip , by 1.4 % in the placebo group ( 95 % CI −2.3 to −0.4 , SD 2.7 , p = 0.006 ) and by 0.7 % in the treatment group ( −1.6 to 0.2 , 2.7 , p = 0.118 ) , difference 0.7 % ( −1.9 to 0.7 , p = 0.332 ) . Findings were not altered by adjustment for sex or serum 25(OH)D. Supplementation with 20,000 IU vitamin D3 a week did not prevent bone loss in this small population . Larger studies are warranted to assess the effect of vitamin D on bone health in persons with MS
For hip fracture , at a 15 % relative risk , the effect estimate lay between the futility boundary and the inferior boundary , meaning there is reliable evidence that vitamin D supplementation does not reduce hip fractures by this amount , but uncertainty remains as to whether it might increase hip fractures .
The effect estimate lay within the futility boundary at thresholds of 0·5 % for total hip , forearm , and total body bone mineral density , and 1·0 % for lumbar spine and femoral neck , providing reliable evidence that vitamin D does not alter these outcomes by these amounts .
INTERPRETATION Our findings suggest that vitamin D supplementation does not prevent fractures or falls , or have clinical ly meaningful effects on bone mineral density .
There were no differences between the effects of higher and lower doses of vitamin D. There is little justification to use vitamin D supplements to maintain or improve musculoskeletal health .
BACKGROUND The effects of vitamin D on fractures , falls , and bone mineral density are uncertain , particularly for high vitamin D doses .
We aim ed to determine the effect of vitamin D supplementation on fractures , falls , and bone density .